IPO Numbers Dipped In 2023, But 2024 Is Off To A Good Start

Funds Raised This Year Double The Like Period Last Year

There were 21 biopharma initial public offerings in 2023, including J&J’s consumer health spin-out Kenvue, versus 22 in 2022. However, IPO proceeds are rising in 2024.

Initial public offering icon on dark background
The IPO market may rebound in 2024 from big dips in 2022 and 2023 • Source: Shutterstock

Initial public offerings in the US by biopharmaceutical companies dipped slightly to 21 in 2023, including Johnson & Johnson’s spin-out of its consumer health business as Kenvue Inc., from 22 IPOs in 2022, which was down from record-breaking levels in 2020 and 2021. But based on the amount of money raised and the number of companies still trading in positive territory, relative to prior years, 2024 seems to be off to a good start.

There have been eight biopharma IPOs so far in the US this year, the last of which launched in mid-February...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.